Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tardive Dyskinesia Therapeutics Market

Tardive Dyskinesia Therapeutics Market – By Drug (Deutetrabenazine, Valbenazine), Dosage Form (Capsules, Tablets), Distribution Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies) – Global Forecast (2024 ­ 2032)

  • Report ID: GMI9586
  • Published Date: May 2024
  • Report Format: PDF

Tardive Dyskinesia Therapeutics Market Size

Tardive Dyskinesia Therapeutics Market size was valued at USD 3.1 billion in 2023 growing at a CAGR of 7.1% between 2024 and 2032, driven by factors such as the increase in the prevalence of tardive dyskinesia (TD).

Tardive Dyskinesia Therapeutics Market

For instance, as per the report published by Mental Health America, it has been reported that, tardive dyskinesia is estimated to affect at least 600,000 people in the U.S. alone. Anyone who has been treated for schizophrenia, schizoaffective disorder, bipolar disorder, anxiety, and/or depression and has taken or is taking psychotropic drugs is at risk for developing TD. Also, the risk for developing TD increases if the patients are 55 years of age or older, postmenopausal, have a history of substance abuse, or have a mood disorder. Thus, the rise in the prevalence of neurological disorders along with increase in consumption of antipsychotic drugs will spur the market growth.

Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused using dopamine receptor blocking drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of antipsychotic drugs and gastrointestinal therapeutics may produce biochemical abnormalities in the brain known as the striatum. The movement disorders include akathisia, dystonia, buccolingual stereotypy, myoclonus, chorea, tics, and other abnormal involuntary movements, which are commonly caused by the long-term use of typical antipsychotics.


Tardive Dyskinesia Therapeutics Market Trends

The rising prevalence of tardive dyskinesia (TD) is significantly propelling the growth of the TD therapeutics market. As per recent statistics it has been indicated that approximately 20-30% of individuals on long-term antipsychotic therapy develop TD, highlighting the widespread impact of this condition.

  • For instance, as per the report published in Healthline in February 2022, in the U.S. alone, an estimated 500,000 to 700,000 people are affected by TD. This growing patient population drives the demand for effective therapeutic options, prompting increased research and development efforts. Thus, the introduction of novel treatments such as VMAT2 inhibitors like valbenazine and deutetrabenazine, has enhanced symptomatic management, thereby contributing to market growth.
  • Additionally, the increase in awareness among healthcare providers and improved diagnostic techniques are leading to more timely and accurate diagnoses, further boosting the demand for TD therapeutics.

Tardive Dyskinesia Therapeutics Market Analysis

Tardive Dyskinesia Therapeutics Market, By Drug, 2021 – 2032  (USD Billion)

Based on the drug, the global market is classified into deutetrabenazine, valbenazine and other drugs. The valbenazine segment dominated the market with revenue of USD 1.6 billion in 2023.

  • Valbenazine, marketed under the brand name Ingrezza, is a drug specifically approved for the treatment of tardive dyskinesia (TD. The drug has demonstrated significant efficacy in reducing the symptoms of tardive dyskinesia in clinical trials, leading to improved patient outcomes. Therefore, the drug has a relatively favorable safety profile with manageable side effects, which increases its acceptance among healthcare providers and patients.
  • Moreover, improved awareness and diagnosis among healthcare providers and advancements in diagnostic methods have led to earlier and more accurate diagnosis of TD, prompting timely intervention and treatment, thereby driving the growth of the market.
Tardive Dyskinesia Therapeutics Market, By Dosage Form (2023)

Based on the dosage form, the global tardive dyskinesia therapeutics market is classified into capsules, and tablets. The tablets segment dominated the market with market share of 54% in 2023.

  • Tablets are easy to administer compared to other forms of medication, such as injections, enhancing patient compliance. Also, tablets prescribed for tardive dyskinesia have demonstrated significant efficacy in clinical trials, which boosts their adoption by healthcare providers and patients.  
  • Further, advances in drug formulation technology have led to the development of more effective and patient-friendly tablet forms, such as extended-release tablets that require less frequent dosing. Thus, growing number of patients diagnosed with TD along with several benefits associated with tablet dosage form accelerates the market growth.

Based on distribution channel, the tardive dyskinesia therapeutics market is classified into hospital pharmacies, drugs store & retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to exhibit 7.4% CAGR between 2024 - 2032.

  • Hospitals often have specialized departments and experts in neurology and psychiatry that are well-equipped to diagnose and treat TD effectively. Also, hospitals possess advanced diagnostic equipment that enables accurate and early detection of TD, facilitating timely and appropriate therapeutic interventions. Such aforementioned factors are anticipated to propel the growth of the market.
  • Further, hospitals are frequently involved in clinical trials and research studies, providing access to cutting-edge therapies and experimental treatments that may not be available elsewhere. Thus, the adoption of latest treatments such as FDA-approved therapies and integrate them into the treatment protocols will augment the segmental growth.
North America Tardive Dyskinesia Therapeutics Market, 2021 – 2032  (USD Billion)

In 2023, North America secured a substantial market share of 44.2% in the global tardive dyskinesia therapeutics market and is expected to dominate throughout the forecast period.

  • The availability of well-established healthcare infrastructure and access to medical facilities, timely diagnosis and treatment for tardive dyskinesia drives the demand for tardive dyskinesia therapeutics in this region.
  • Also, the presence key players and specialized clinics and centers with expertise in movement disorders ensures better management of the disease, thus boosting the growth of the market.
  • Furthermore, availability of new pipeline drugs for tardive therapeutics will increase the product demand which in turn will propel the growth of the market during the forecast period.  

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.

  • The rising healthcare expenditure in Germany along with the availability of healthcare resources and reimbursement policies for neurological and psychiatric disorders ensure that patients have access to a range of treatment options, including therapeutics for tardive dyskinesia.
  • Also, the increase in collaborations between pharmaceutical companies, academic institutions, and healthcare organizations facilitate the development and commercialization of new therapeutics for tardive dyskinesia. Such aforementioned factors are expected to supplement the country level market growth.

The India and China tardive dyskinesia therapeutics market is expected to grow with a significant CAGR during the forecast period.

  • Improvements in healthcare infrastructure, including the expansion of hospitals, clinics, and healthcare facilities, can increase access to diagnosis and treatment for tardive dyskinesia. Also, the increase in the number of government initiatives and policies aimed at addressing mental health issues including National Mental Health Program (NMHP) in Inda, can cover provisions for improving access to treatment for tardive dyskinesia and related conditions.
  • Thus, constant support from government is anticipated to foster the growth of the market in both the country.

Tardive Dyskinesia Therapeutics Market Share

The competitive landscape of the market is characterized by the presence of established companies that manufacture advanced tardive dyskinesia therapeutics products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for tardive dyskinesia therapeutics.

Tardive Dyskinesia Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in market as well as those that are into clinical phase development. Prominent players operating in the tardive dyskinesia therapeutics industry are as mentioned below:

  • H. Lundbeck A/S
  • Luye Pharma Group
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences Inc.
  • SteriMax Inc.
  • SOM Biotech
  • Teva Neuroscience, Inc.

Tardive Dyskinesia Therapeutics Industry News:

  • In February 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDOXR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). This strategy enabled company to strengthen their product offerings.
  • In June 2022, Mitsubishi Tanabe Pharma Corporation a member of the Mitsubishi Chemical Holdings Group, announced that MTPC is launching DYSVAL capsules 40mg (the vesicular monoamine transporter type 2 (VMAT2) inhibitor) for the treatment of tardive dyskinesia in Japan. This strategy enabled company to expand its customer base.

The tardive dyskinesia therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug

  • Deutetrabenazine
  • Valbenazine
  • Other drugs

Market, By Dosage Form

  • Capsules
  • Tablets

Market, By Distribution channel

  • Hospital pharmacies
  • Drug store & retail pharmacies
  • Online pharmacies  

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • The Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudia Arabia
    • UAE
    • Rest of Middle East and Africa
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global tardive dyskinesia therapeutics market size was valued at USD 3.1 billion in 2023 and will grow at 7.1% CAGR during 2024-2032, driven by the increasing prevalence of tardive dyskinesia.

The valbenazine drug type segment in the market recorded USD 1.6 billion in 2023 and will grow rapidly through 2032, as the drug has demonstrated significant efficacy in reducing the symptoms of tardive dyskinesia in clinical trials.

North America secured 44.2% of the tardive dyskinesia therapeutics market share in 2023 and will expand at a steady pace through 2032, owing to the availability of well-established healthcare infrastructure and access to medical facilities.

H. Lundbeck A/S, Luye Pharma Group, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., SteriMax Inc., SOM Biotech, and Teva Neuroscience, Inc. among others.

Tardive Dyskinesia Therapeutics Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 7
  • Tables & Figures: 112
  • Countries covered: 22
  • Pages: 147
 Download Free Sample